Tnfsf11 Knockout cell line (MLO-Y4)
Catalog Number: KO01190
Price: Online Inquiry
Catalog Number: KO01190
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Tnfsf11 Knockout cell line (MLO-Y4) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epithelioid, adherent cell |
Passage ratio | 1:3~1:4 |
species | Mouse |
Gene | Tnfsf11 |
Gene ID | 21943 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90% Alpha MEM+10%FBS |
Parental Cell Line | MLO-Y4 |
Quality Control | Genotype: Tnfsf11 Knockout cell line (MLO-Y4) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | tumor necrosis factor (ligand) superfamily, member 11provided by MGI |
Also known as | ODF; OPGL; RANKL; Ly109l; Trance |
Gene Description | Enables identical protein binding activity; receptor ligand activity; and tumor necrosis factor receptor superfamily binding activity. Involved in several processes, including intracellular signaling cassette; positive regulation of secretion by cell; and regulation of DNA-templated transcription. Acts upstream of or within several processes, including cellular response to cytokine stimulus; mammary gland development; and positive regulation of intracellular signal transduction. Predicted to be located in cytoplasm and plasma membrane. Predicted to be active in extracellular space. Is expressed in bone; genitourinary system; hemolymphoid system; incisor; and rib. Used to study autosomal recessive osteopetrosis 2 and osteoporosis. Human ortholog(s) of this gene implicated in autosomal recessive osteopetrosis 2 and osteoporosis. Orthologous to human TNFSF11 (TNF superfamily member 11). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Biased expression in thymus adult (RPKM 1.0), mammary gland adult (RPKM 0.5) and 8 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.